This site is intended for U.S. residents only.

Sign Up for Continued Support

The support you need throughout treatment

Whether you are currently being treated with KYPROLIS® or are just interested in learning more, you don't have to go through it alone thanks to the KYPROLIS® Support Program.

Patients who sign up will receive:

Informational emails about KYPROLIS® and relapsed multiple myeloma

Direct mail containing KYPROLIS® support materials and additional information about treatment-related topics

The information you receive from KYPROLIS® is not meant to replace the advice of your healthcare team. Amgen will not provide medical advice regarding your medical condition. The KYPROLIS® Support Program is not intended to diagnose health problems or to take the place of talking with your doctor about your condition, treatment, or medication. Be sure to talk to your doctor at your next visit if you have any questions about relapsed multiple myeloma or KYPROLIS®.

Fill out the form below so that you can receive information on how to start KYPROLIS®, what to do once you start, and everything in between, directly in your inbox and mailbox.

Are you or someone you know currently being treated with KYPROLIS®?


*All fields are required unless marked as optional.


Are you interested in inspiring others by telling your story?

If so, you may want to join the Voices of Experience program. Voices of Experience is a volunteer program for adults with relapsed or refractory multiple myeloma who are receiving KYPROLIS® or who received KYPROLIS® in the past and would like to share their real-life experiences.

If you select "Yes," you agree to share your personal health information with a Voices of Experience representative who may contact you regarding your participation in the Voices of Experience program.



Privacy Notice and Patient Authorization

*Please read and accept the Privacy Notice

Amgen's Privacy Pledge to Patients

Amgen respects patients and customers and takes the protection of their privacy very seriously.

Amgen pledges the following:

- Amgen does not and will not sell or rent your information to marketing companies or mailing list brokers.

- Amgen is careful to only collect and/or use personal identifiable information for the purposes stated in this Authorization and as necessary to provide the services and/or programs, the patient or customer chooses to enroll into.

- Amgen practices are consistent with federal and state privacy laws, including HIPAA.

Amgen program enrollment is voluntary and always provides patients with an easy option to cancel participation.

Privacy Notice and Patient Authorization

I authorize Amgen and its contractors (“Amgen”) to use and/or disclose my personal information, including my personal health information, for the following purposes: (1) to enroll me in and/or continue my participation in Amgen’s KYPROLIS® Support Program and related activities; (2) to provide me with informational and marketing materials relating to Amgen products and services, and/or my condition or treatment; and/or (3) to improve, develop, evaluate and continue products, services, materials and programs related to my condition or treatment. I understand that I may be contacted by mail and/or email for any of these purposes. I further understand that the KYPROLIS® Support Program and additional informational and marketing communications are optional and free services. I do not have to sign this authorization and this authorization in no way affects my right to obtain any medications. To obtain a copy of this authorization or to cancel at any time, I can contact Amgen by calling [1-888-427-7478] or by writing to [Amgen P.O. Box 681308 Indianapolis, IN 46268]. The Amgen privacy policy can be found at http://wwwext.amgen.com/privacy-statement.


By clicking the "I accept" button, I am electronically indicating that I have read and understood Amgen’s Privacy Notice and Patient Authorization (above in its full text), that I am legally authorized to consent and that I am providing my consent as the patient or the patient's legal guardian for Amgen and its contractors and business partners to use and share the personal information I provide for the purposes described within the Privacy Notice and Patient Authorization. By clicking "Cancel" below, my activation and enrollment into the KYPROLIS® Support Program will be discontinued.

This is a security feature to enhance your protection. Type the characters you see in the picture below.

Characters are not case sensitive.

CAPTCHA
Change the CAPTCHA codeSpeak the CAPTCHA code
 

IMPORTANT SAFETY INFORMATION

KYPROLIS® (carfilzomib) can cause serious side effects:
  • Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
  • Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
  • Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
  • Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
  • Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
  • Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
  • High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
  • Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
  • If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
  • If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone.
  • Infusion reactions: Symptoms of infusion reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
  • Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
  • Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
  • Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
  • Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
  • Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
  • KYPROLIS should not be combined with melphalan and prednisone: Newly diagnosed transplant ineligible multiple myeloma patients have shown an increased risk of serious and fatal side effects when using KYPROLIS in combination with melphalan and prednisone.
  • Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should avoid becoming pregnant during treatment with KYPROLIS and for 6 months following the final dose. Men should avoid fathering a child during treatment with KYPROLIS and for 3 months following the final dose. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
  • Shortness of breath
  • Prolonged, unusual or excessive bleeding
  • Yellowing of the skin and/or eyes (jaundice)
  • Headaches, confusion, seizures, or loss of sight
  • Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
  • Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, low white blood cell count, diarrhea, difficulty breathing, tiredness (fatigue), low platelets, fever, sleeplessness (insomnia), muscle spasm, cough, upper airway (respiratory tract) infection, and decreased potassium levels.
  • The most common side effects occurring in at least 20% of patients receiving KYPROLIS when used alone (monotherapy) in trials are: low red blood cell count, tiredness (fatigue), low platelets, nausea, fever, difficulty breathing, diarrhea, headache, cough, swelling of the lower legs or hands.

These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Product Information.

APPROVED USES

  • KYPROLIS® (carfilzomib) is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma.
  • KYPROLIS® is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one or more previous treatments for multiple myeloma. KYPROLIS is approved for use alone to treat relapsed or refractory multiple myeloma.